Enter multiple symbols separated by commas

Search results for "CELL"



About 74 results. Sort By: Date | Relevance
Brady's suspension details & developments  

Bob Kravitz, WTHR.com, weighs in on Tom Brady and his four game suspension.
Source: CNBC.com
Patriots owner: I was wrong to put faith in NFL

"I've come to the conclusion that this was never about doing what was fair and just," Patriots Owner Robert Kraft said.
Source: CNBC.com | By: Everett Rosenfeld
Patriots owner: Tom Brady a person of great integrity  

New England Patriots owner Robert Kraft comments on the decision Tom Brady will be suspended for 4 games.
Source: CNBC.com
NFL upholds Tom Brady's 4-game suspension

The NFL said Tuesday that it has upheld its four-game suspension of New England Patriots Quarterback Tom Brady.
Source: CNBC.com | By: Everett Rosenfeld
CNBC update: $150k bag of cash  

The Centers for Medicare and Medicaid now estimate that spending grew slightly less than expected in 2014, but topped $3 trillion, and thieves made off with $150,000 in cash left behind by ATM employees, reports CNBC's Sue Herera.
Source: CNBC.com
CNBC update: NFL upholds Tom Brady's suspension  

Representatives from 70 countries are meeting in Spain on counter-terrorism strategies, and NFL Commissioner Roger Goodell has upheld the 4 game suspension of Tom Brady, reports CNBC's Sue Herera.
Source: CNBC.com
A path to conquering cancer: NantKwest CEO  

Immunotherapy biotech company NantKwest shares opened at $37 in their trading debut, 48% above their IPO price. Patrick Soon-Shiong ,NantKwest CEO, discusses the company and success toward fighting cancer with "natural killers"
Source: CNBC.com
Merck expanding cancer drug pipeline: CEO  

CNBC's Meg Tirrell talks with Merck CEO Ken Frazier about the company's lung cancer drug Keytruda, and other drugs in the pipeline. Also Frazier weighs in on M&A in the pharma space and pricing pressures.
Source: CNBC.com
Merck tops Street 2Q forecasts despite lower sales, profit

Merck& Co.' s second-quarter profit plunged by two-thirds, hammered by the sale of its consumer business, unfavorable currency exchange rates, lower sales of some key drugs and hefty one-time charges. The world's fifth-biggest drugmaker by revenue beat modest Wall Street expectations and raised its full-year profit forecast by a dime per share, but shares...
Source: The Associated Press
Cramer's shopping list for a pullback  

Mad Money's Jim Cramer goes through his list of mine-resistant stocks to see if there are any bargains.
Source: CNBC.com